Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Acer Therapeutics is a biotechnology business based in the US. Acer Therapeutics shares (ACER) are listed on the NASDAQ and all prices are listed in US Dollars. Acer Therapeutics employs 41 staff and has a trailing 12-month revenue of around $360,000.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $2.22 |
|---|---|
| 52-week range | $1.11 - $4.56 |
| 50-day moving average | $2.46 |
| 200-day moving average | $1.79 |
| Wall St. target price | $8.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.39 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.22 from 2023-02-07
| 1 week (2023-02-02) | 2.30% |
|---|---|
| 1 month (2023-01-09) | -19.86% |
| 3 months (2022-11-09) | 85.00% |
| 6 months (2022-08-09) | 46.05% |
| 1 year (2022-02-09) | -5.13% |
|---|---|
| 2 years (2021-02-09) | -42.64% |
| 3 years (2020-02-07) | 4.53 |
| 5 years (2018-02-09) | 18 |
| Revenue TTM | $360,000 |
|---|---|
| Gross profit TTM | $1.3 million |
| Return on assets TTM | -62.07% |
| Return on equity TTM | -472.99% |
| Profit margin | 0% |
| Book value | $-0.75 |
| Market capitalisation | $43.7 million |
TTM: trailing 12 months
We're not expecting Acer Therapeutics to pay a dividend over the next 12 months.
Acer Therapeutics's shares were split on a 96:1000 basis on 20 September 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 96 shares. This wouldn't directly have changed the overall worth of your Acer Therapeutics shares – just the quantity. However, indirectly, the new 941.7% higher share price could have impacted the market appetite for Acer Therapeutics shares which in turn could have impacted Acer Therapeutics's share price.
Over the last 12 months, Acer Therapeutics's shares have ranged in value from as little as $1.109 up to $4.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acer Therapeutics's is 0.6802. This would suggest that Acer Therapeutics's shares are less volatile than average (for this exchange).
Acer Therapeutics Inc. , a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.